Fig. 2From: Improvement of synaptic plasticity and cognitive function in RASopathies—a monocentre, randomized, double-blind, parallel-group, placebo-controlled, cross-over clinical trial (SynCoRAS)Graphical flow-chart of the study design for NF1 (experiment III). In experiment III, patients with NF1 first receive lamotrigine (LTG) or placebo (PLC) with a minimum pause of 7 days and maximum of 60 daysBack to article page